Simron Singh, MD, MPH, of Sunnybrook Health Sciences Centre, discusses initial results of his data on a new patient experience measurement strategy used at Cancer Care Ontario.
Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.
Aaron Lyss, MBA, of Tennessee Oncology, discusses ways that clinicians and patients can employ the most cost- and treatment-effective measures, clinical trials, and incident learning systems.
Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre, summarized the Keynote Lecture, including the points that clinicians should carefully plan their quality improvement projects, understand the barriers to quality, and ensure their efforts are sustainable.
Fumiko Ladd Chino, MD, of Duke University, discusses results from a population study she conducted of the opioid epidemic over the past 10 years and why these medications for cancer pain should continue to be excluded from restrictive-prescribing laws (Abstract 230).
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, for better shared decision-making (Abstract 159).
